The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Latest knowledge has utilized enhanced evaluation of digital patient-reported outcomes (ePROs) to establish undetected signs whereas bettering symptom administration for sufferers with numerous...
In the end, the U.S. Facilities for Medicare and Medicaid Companies (CMS) is now backing Medicare reimbursement for CT colonography (CTC) in colorectal...
